Denosumab (anti-TNFSF11)

Name: Denosumab (anti-TNFSF11)
Brand: MedChemExpress
SKU: HY-P9958A
Rating: 4.5 (1 reviews)

Cat. No.: HY-P9958A Purity: 95.00%: FAQs
Data Sheet SDS COA

Molarity Calculator

Denosumab (anti-TNFSF11) is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (K_D of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies.

For research use only. We do not sell to patients.

Denosumab (anti-TNFSF11) Chemical Structure

CAS No. : 615258-40-7

Size	Stock	Quantity
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Denosumab (anti-TNFSF11):

Denosumab Get quote

1 Publications Citing Use of MCE Denosumab (anti-TNFSF11)

•Regen Ther. 2024 Dec, 27, Pages 181-190.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All NF-κB Isoform Specific Products:

View All Isoforms

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

Biological Activity
Purity & Documentation
References
Customer Review

Description

Isotype

Human IgG2 kappa

Recommend Isotype Controls

Human IgG2 kappa, Isotype Control

Species

Human

In Vitro

Denosumab (0.25-20 μM, 7 days) enhances osteogenic differentiation at physiological concentrations in human mesenchymal stem cells of the jaw bone^[4].
Denosumab (0.1 μM–5 μM) alleviates ROS-induced chondrocytes Apoptosis, with promoting Bcl-2 and suppressing pro-apoptotic genes Bax and caspase-3^[5].
Denosumab (5 μM, 5-60 min) suppresses RANKL-induced osteoclastogenesis by inhibiting the NF-κB signaling pathway^[5].
Denosumab (0.001-0.1 μg/mL, 24-72 h) significantly increases human β-cell proliferation^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Differentiation Assay^[4]

Cell Line:	mesenchymal stem cells of the jaw bone
Concentration:	0.25, 1, 5, 20 μM
Incubation Time:	7 days
Result:	Increased ALP activity at 0.25 μM, 1 μM and 5 μM. Enhanced ALP activity at 1 μM and 5 μM significantly more than 0.25 μM. Decreased ALP activity at 20 μM. upregulated the key enzymes of osteogenic differentiation ALP, COL1 and RUNX2 at 0.25 μM.

Western Blot Analysis^[5]

Cell Line:	peripheral blood mononuclear cells (PBMCs)
Concentration:	5 μM
Incubation Time:	5, 10, 60 min
Result:	Reversed the increased phosphorylation of IκBα and p65. had an impact on the phosphorylation of p38.

In Vivo

Denosumab (10 mg/kg, s.c., twice a week for 4 weeks) ameliorates pain-related behaviors and osteoarthritis (OA) progression in the OA mouse model^[5].
Denosumab (1 mg/kg, s.c., single) enhances human β-cell proliferation in human islets transplanted under the kidney capsule of male euglycemic NOD/SCID mice^[6].
Denosumab (5 mg/kg, s.c., single) increases testis weight, inhibin B, and sperm count in humanized RANKL mice^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	mouse DMM model of OA (induced through surgical destabilization of the medial meniscus for 5-week-old male NOD-SCID mice irradiated with a sublethal dose (1.0 Gy) and then injected intravenously with 2 × 10⁴ human CD34⁺ monocytes)^[5]
Dosage:	10 mg/kg
Administration:	Subcutaneous injection (s.c.), twice a week, 4 weeks
Result:	Increased footprint area, increased intensity, reduced swing, increased swing speed and increased stand time. Inhibited subchondral bone resorption. Restored articular cartilage and proteoglycan. Inhibited early hyperactivity of the osteoclasts. Attenuated chondrocyte apoptosis in degenerated cartilage induced by DMM surgery. Reduced the enlargement of the lining cell layer, cellular density of synovial stroma, and leukocytic infiltrate.

CAS No.

615258-40-7

Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Denosumab (anti-TNFSF11)]

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Purity: 95.00%

Select Batch:

Data Sheet (267 KB) SDS (251 KB)

COA (231 KB)

Inhibitory Antibodies User Guide (602 KB)

References

[1]. 1. Moen MD, et al. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging. 2011;28(1):63-82. [Content Brief]

[2]. 2. Kendler DL, et al. Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review. Adv Ther. 2022 Jan;39(1):58-74. [Content Brief]

[3]. 3. Dell'Aquila E, et al. Denosumab for cancer-related bone loss. Expert Opin Biol Ther. 2020 Nov;20(11):1261-1274. [Content Brief]

[4]. 4. Mosch A, et al. Physiological concentrations of denosumab enhance osteogenic differentiation in human mesenchymal stem cells of the jaw bone. Arch Oral Biol. 2019 May;101:23-29. [Content Brief]

[5]. 5. Shangguan L, et al. Denosumab ameliorates osteoarthritis by protecting cartilage against degradation and modulating subchondral bone remodeling. Regen Ther. 2024 Mar 26;27:181-190. [Content Brief]

[6]. 6. Kondegowda NG, et al. Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the Receptor Activator of NF-κB Ligand Pathway. Cell Metab. 2015 Jul 7;22(1):77-85. [Content Brief]

[7]. 7. Andreassen CH, et al. Denosumab stimulates spermatogenesis in infertile men with preserved Sertoli cell capacity. Cell Rep Med. 2024 Oct 15;5(10):101783. [Content Brief]